Skip to content
  • Home
  • Company
    • About Us
    • Leadership
    • Management
    • Board of Directors
    • Scientific
      Advisory Board
  • Science
    • Evorpacept
    • Publications
  • Pipeline
    • Clinical Trials
    • Expanded
      Access Policy
  • Careers
    • Current Jobs
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • IR Resources
  • Contact

Oral Presentation: ALX148 is a High Affinity SIRPα Fusion Protein that Blocks CD47, Enhances the Activity of Anti-Cancer Antibodies and Checkpoint Inhibitors, and Has a Favorable Safety Profile in Preclinical Models

Post navigation

Previous: ALX148 is a High Affinity SIRPα Fusion Protein that Blocks CD47, Enhances the Activity of Anti-Cancer Antibodies and Checkpoint Inhibitors, and Has a Favorable Safety Profile in Preclinical Models
Next: A Phase 1 Study of ALX148, a CD47 Blocker, Alone and in Combination with Established Anti-Cancer Antibodies in Patients with Advanced Malignancy and Non Hodgkin Lymphoma
TOP
  • Home
  • Company
    • About Us
    • Leadership
    • Management
    • Board of Directors
    • Scientific
      Advisory Board
  • Science
    • Evorpacept
    • Publications
  • Pipeline
    • Clinical Trials
    • Expanded
      Access Policy
  • Careers
    • Current Jobs
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • IR Resources
  • Contact
© ALX Oncology Inc., All rights reserved.
Privacy Policy Twitter LinkedIn